Inhibition of streptozocin-induced insulitis and diabetes with lobenzarit in CD-1 mice.
When multiple low doses (30 mg/kg body wt) of streptozocin were given to CD-1 mice, diabetes associated with L3T4 T-lymphocyte- and B-lymphocyte-predominant insulitis occurred. Thus, a model of type I (insulin-dependent) diabetes was obtained. To treat these diabetic mice, we administered lobenzarit (CCA), a newly synthesized immunomodulator. CCA (2 or 10 mg/kg body wt) significantly inhibited the progression of diabetes by suppressing the severity and incidence of insulitis. Insulin contents of the pancreas were preserved. The possibility that autoimmune-related diabetes can be treated with CCA warrants further attention.
Iwakiri
R
R
First Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Nagafuchi
S
S
D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy*; D006943:Hyperglycemia / Q000188:drug therapy; D007515:Islets of Langerhans / Q000187:drug effects*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D062367:ortho-Aminobenzoates / Q000627:therapeutic use*
D001786:Blood Glucose; D062367:ortho-Aminobenzoates; C015735:lobenzarit